GLP-1 Medications and Mental Health:
What the Research Shows

In early 2023, the European Medicines Agency (EMA) began reviewing approximately 150 reports of self-harm and suicidal thoughts in patients taking semaglutide and liraglutide. The FDA followed with its own investigation, reviewing its FAERS (FDA Adverse Event Reporting System) database.

In January 2024, the FDA announced its preliminary findings: the available evidence did not indicate a causal association between GLP-1 receptor agonists and suicidal ideation or self-harm. The EMA reached a similar conclusion.

This doesn't mean the reports were false. It means that when you compare the rate of suicidal thoughts in GLP-1 users against the background rate in the general population — especially in a population with obesity, which itself carries elevated rates of depression — the GLP-1 group didn't show a statistically significant increase.

The investigation remains ongoing. The FDA has asked manufacturers to continue monitoring and reporting mental health-related adverse events. Additional studies, including analyses of large insurance claims databases, are underway.

The STEP trials (semaglutide) and SURMOUNT trials (tirzepatide) included mental health questionnaires as secondary endpoints. Here's what they found:

• STEP 1 (semaglutide 2.4 mg, 68 weeks): Participants on semaglutide showed improvement in depression scores (PHQ-9) compared to placebo. The weight loss itself appeared to drive improved mood.
• STEP 5 (semaglutide, 2 years): Longer-term data confirmed sustained improvements in quality of life scores, including mental health domains, throughout the 104-week treatment period.
• SURMOUNT-1 (tirzepatide): Quality of life improvements were significant across all tirzepatide doses compared to placebo, with the greatest improvements in patients who lost the most weight.
• A 2024 retrospective study analyzing over 240,000 electronic health records found that patients on semaglutide had a lower incidence of newly diagnosed depression compared to matched controls not on GLP-1 medications.

Taken together, the clinical trial data leans positive: on average, GLP-1 medications are associated with improved mental health, not worsened. But averages can mask individual experiences.

Many GLP-1 users report significant psychological benefits. These are real, documented, and often life-changing:

• Food noise relief: This is the most commonly reported psychological benefit. The constant mental chatter about food — what to eat, when to eat, the guilt after eating, the planning, the cravings — goes quiet. Users describe this as "freedom," "peace," and "what I imagine normal people feel like." For people who have spent decades in a dysfunctional relationship with food, this silence is profound.
• Reduced compulsive behavior: Emerging research and user reports suggest GLP-1 medications may reduce compulsive behaviors beyond eating — including alcohol cravings, compulsive shopping, and nail-biting. The brain's reward pathways are being modulated in ways we don't fully understand yet.
• Improved body image: Weight loss itself improves body image and self-esteem for most people, but the effect goes beyond the scale. Fitting into clothes, moving more easily, and receiving social feedback all contribute.
• Increased confidence and social engagement: Many users report becoming more socially active, more willing to try new activities, and less avoidant of situations where their weight felt like a barrier.
• Better sleep: Weight loss often improves sleep apnea, which in turn improves mood, cognition, and energy. This creates a positive cascade.

A minority of users report negative mental health effects. These deserve serious attention even if they're not the majority experience:

• Depression during the adjustment period: Some users report new or worsening depression in the first 4–8 weeks of treatment. This may relate to rapid dietary changes, hormonal shifts from fat loss, social adjustment to a changed relationship with food, or direct neurological effects that vary by individual.
• Loss of food as a coping mechanism: For people who used eating as their primary emotional regulation tool, removing that coping mechanism without replacing it can leave a psychological void. Therapists specializing in obesity and eating disorders call this "losing the anesthetic."
• Anhedonia and flat affect: Some users report feeling emotionally "flat" — not depressed exactly, but less able to experience pleasure from food, social events, or activities they previously enjoyed. This may relate to GLP-1's effects on dopamine reward pathways.
• Anxiety around eating: Nausea and GI side effects can create anticipatory anxiety about meals. Some users develop a pattern of eating avoidance that borders on disordered eating.
• Identity disruption: Rapid body changes can be psychologically disorienting. Some users report feeling like they don't recognize themselves, or feeling grief about "lost years" spent at a higher weight.

Based on the available evidence and clinical consensus, certain groups should be more closely monitored for mental health effects:

• Pre-existing depression or anxiety: If you have a history of depression, anxiety, or other mood disorders, you should establish a baseline mood assessment before starting a GLP-1 medication and monitor closely during the first 3 months. The medication may improve or worsen your baseline — but you need a baseline to compare against.
• History of eating disorders: GLP-1 medications interact with eating disorder psychology in complex ways. They can reduce binge urges but may also reinforce restriction patterns. Anyone with a history of anorexia, bulimia, or binge eating disorder should work with a therapist familiar with both GLP-1 medications and eating disorders.
• Social isolation: People with limited social support may be more vulnerable to negative mood effects, especially if food was a primary source of comfort.
• Rapid weight loss: Losing more than 1% of body weight per week is associated with higher rates of mood disruption, fatigue, and muscle loss. Tracking weight and mood together can help identify when the rate of loss is becoming problematic.
• Concurrent major life changes: Starting a GLP-1 during a divorce, job loss, move, or other major stressor makes it harder to attribute mood changes to the medication versus life circumstances.

Contact your prescriber or a mental health professional if you experience:

• Persistent depressed mood lasting more than 2 weeks after starting or changing doses
• Loss of interest in activities you previously enjoyed
• Significant changes in sleep patterns not explained by other factors
• Thoughts of self-harm or suicide (this is urgent — call 988 or go to the ER)
• Increasing anxiety around food that feels uncontrollable
• Withdrawal from social activities or relationships
• Feelings of emotional numbness that persist beyond the first few weeks

These symptoms are not "just side effects to push through." They are signals that your treatment plan may need adjustment — whether that's a dose change, a pause, the addition of therapy, or a different medication entirely.

Here's the problem with mental health monitoring on GLP-1 medications: most prescriber visits happen every 4–8 weeks. You walk in, your doctor asks "how are you feeling," and you give a snapshot answer based on that day. But mood is not a snapshot — it's a trend.

A week of low mood after a dose increase is very different from a month-long downward trend. A few bad days are very different from a pattern where every injection day is followed by 48 hours of irritability. These patterns are invisible without tracking, and they're invisible to your prescriber without data.

• Rate your mood daily — even a simple 1–5 scale, logged consistently, creates a trendline your prescriber can actually use.
• Note your injection days — correlating mood shifts with injection timing reveals patterns that are clinically actionable.
• Log major life events — this helps separate medication effects from situational factors.
• Track food noise — the presence or absence of food noise is one of the most useful indicators of whether the medication is working as expected.

The best available evidence says GLP-1 medications, on average, improve mental health — primarily through weight loss, food noise reduction, and improved quality of life. The FDA investigation did not find a causal link to suicidal ideation. But individual experiences vary widely, and a minority of users do experience negative mood effects that deserve clinical attention.

The answer is not to avoid these medications out of fear. It's to monitor your mental health as carefully as you monitor your weight — daily, consistently, and with enough data that your prescriber can distinguish a bad week from a concerning trend.